Literature DB >> 20538760

The combination of a histone deacetylase inhibitor with the Bcl-2 homology domain-3 mimetic GX15-070 has synergistic antileukemia activity by activating both apoptosis and autophagy.

Yue Wei1, Tapan Kadia, Weigang Tong, Ming Zhang, Yu Jia, Hui Yang, Yumin Hu, Francesco Paolo Tambaro, Jean Viallet, Susan O'Brien, Guillermo Garcia-Manero.   

Abstract

PURPOSE: Single-agent histone deacetylase inhibitors (HDACi) have limited clinical activity in human leukemia. Although the way HDACi exert their antileukemia effect is not fully understood, it is accepted that induction of apoptosis is important. We hypothesized, therefore, that combination of an HDACi with a proapoptotic agent, such as the Bcl-2 homology domain-3 mimetic GX15-070, could result in enhanced antileukemia activity. EXPERIMENTAL
DESIGN: We analyzed the cellular and molecular effects of two different HDACi (MGCD0103 and vorinostat) in combination with GX15-070 in leukemia cell lines and primary acute myelogenous leukemia cells.
RESULTS: We showed that the combination had synergistic antileukemia effect both in leukemia cell lines and in primary acute myelogenous leukemia cells. Using molecular markers and electron microscopy, we observed that in addition to apoptosis, autophagy accounts for the nonapoptotic decrease in cell viability, an effect that could be inhibited by chloroquine, an inhibitor of autophagy. Finally, we established a role for calpain activity in the induction of both autophagy and apoptosis by this combination.
CONCLUSIONS: The combination of an HDACi and GX15-070 has synergistic antileukemia activity, and the effect is mediated by induction of apoptosis and autophagy. The combination should be studied in clinical trials of leukemia and the role of autophagy in leukemia therapy needs to be better understood. (c) 2010 AACR.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20538760      PMCID: PMC4113507          DOI: 10.1158/1078-0432.CCR-10-0032

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  39 in total

1.  LC3, a mammalian homologue of yeast Apg8p, is localized in autophagosome membranes after processing.

Authors:  Y Kabeya; N Mizushima; T Ueno; A Yamamoto; T Kirisako; T Noda; E Kominami; Y Ohsumi; T Yoshimori
Journal:  EMBO J       Date:  2000-11-01       Impact factor: 11.598

2.  The pre-autophagosomal structure organized by concerted functions of APG genes is essential for autophagosome formation.

Authors:  K Suzuki; T Kirisako; Y Kamada; N Mizushima; T Noda; Y Ohsumi
Journal:  EMBO J       Date:  2001-11-01       Impact factor: 11.598

Review 3.  The glucose-regulated proteins: stress induction and clinical applications.

Authors:  A S Lee
Journal:  Trends Biochem Sci       Date:  2001-08       Impact factor: 13.807

4.  Calpain-mediated X-linked inhibitor of apoptosis degradation in neutrophil apoptosis and its impairment in chronic neutrophilic leukemia.

Authors:  Susumu Kobayashi; Kouhei Yamashita; Tomoharu Takeoka; Tetsuya Ohtsuki; Yasuyuki Suzuki; Ryosuke Takahashi; Kokichi Yamamoto; Scott H Kaufmann; Takashi Uchiyama; Masataka Sasada; Atsushi Takahashi
Journal:  J Biol Chem       Date:  2002-07-16       Impact factor: 5.157

5.  Molecular sequelae of histone deacetylase inhibition in human malignant B cells.

Authors:  Nicholas Mitsiades; Constantine S Mitsiades; Paul G Richardson; Ciaran McMullan; Vassiliki Poulaki; Galinos Fanourakis; Robert Schlossman; Dharminder Chauhan; Nikhil C Munshi; Teru Hideshima; Victoria M Richon; Paul A Marks; Kenneth C Anderson
Journal:  Blood       Date:  2003-01-16       Impact factor: 22.113

Review 6.  Histone deacetylase inhibitors in cancer therapy.

Authors:  Andrew A Lane; Bruce A Chabner
Journal:  J Clin Oncol       Date:  2009-10-13       Impact factor: 44.544

7.  BCL-2 family inhibitors enhance histone deacetylase inhibitor and sorafenib lethality via autophagy and overcome blockade of the extrinsic pathway to facilitate killing.

Authors:  Aditi Pandya Martin; Margaret A Park; Clint Mitchell; Teneille Walker; Mohamed Rahmani; Andrew Thorburn; Dieter Häussinger; Roland Reinehr; Steven Grant; Paul Dent
Journal:  Mol Pharmacol       Date:  2009-05-29       Impact factor: 4.436

8.  Yama/CPP32 beta, a mammalian homolog of CED-3, is a CrmA-inhibitable protease that cleaves the death substrate poly(ADP-ribose) polymerase.

Authors:  M Tewari; L T Quan; K O'Rourke; S Desnoyers; Z Zeng; D R Beidler; G G Poirier; G S Salvesen; V M Dixit
Journal:  Cell       Date:  1995-06-02       Impact factor: 41.582

9.  Cross-talk between two cysteine protease families. Activation of caspase-12 by calpain in apoptosis.

Authors:  T Nakagawa; J Yuan
Journal:  J Cell Biol       Date:  2000-08-21       Impact factor: 10.539

10.  Involvement of caspase-4 in endoplasmic reticulum stress-induced apoptosis and Abeta-induced cell death.

Authors:  Junichi Hitomi; Taiichi Katayama; Yutaka Eguchi; Takashi Kudo; Manabu Taniguchi; Yoshihisa Koyama; Takayuki Manabe; Satoru Yamagishi; Yoshio Bando; Kazunori Imaizumi; Yoshihide Tsujimoto; Masaya Tohyama
Journal:  J Cell Biol       Date:  2004-05-03       Impact factor: 10.539

View more
  31 in total

1.  Obatoclax (GX15-070) triggers necroptosis by promoting the assembly of the necrosome on autophagosomal membranes.

Authors:  F Basit; S Cristofanon; S Fulda
Journal:  Cell Death Differ       Date:  2013-06-07       Impact factor: 15.828

Review 2.  Small molecule inhibitors in acute myeloid leukemia: from the bench to the clinic.

Authors:  Muneera Al-Hussaini; John F DiPersio
Journal:  Expert Rev Hematol       Date:  2014-08       Impact factor: 2.929

Review 3.  Cell death by autophagy: emerging molecular mechanisms and implications for cancer therapy.

Authors:  S Fulda; D Kögel
Journal:  Oncogene       Date:  2015-01-26       Impact factor: 9.867

Review 4.  Histone deacetylase inhibitor (HDACI) mechanisms of action: emerging insights.

Authors:  Prithviraj Bose; Yun Dai; Steven Grant
Journal:  Pharmacol Ther       Date:  2014-04-24       Impact factor: 12.310

5.  Pivotal role of mitophagy in response of acute myelogenous leukemia to a ceramide-tamoxifen-containing drug regimen.

Authors:  Samy A F Morad; Matthew R MacDougall; Noha Abdelmageed; Li-Pin Kao; David J Feith; Su-Fern Tan; Mark Kester; Thomas P Loughran; Hong-Gang Wang; Myles C Cabot
Journal:  Exp Cell Res       Date:  2019-05-18       Impact factor: 3.905

Review 6.  Autophagy as a therapeutic target in cancer.

Authors:  Ning Chen; Vassiliki Karantza
Journal:  Cancer Biol Ther       Date:  2011-01-15       Impact factor: 4.742

Review 7.  Autophagy modulation for cancer therapy.

Authors:  Zhineng J Yang; Cheng E Chee; Shengbing Huang; Frank Sinicrope
Journal:  Cancer Biol Ther       Date:  2011-01-15       Impact factor: 4.742

Review 8.  Mocetinostat (MGCD0103): a review of an isotype-specific histone deacetylase inhibitor.

Authors:  Yanis Boumber; Anas Younes; Guillermo Garcia-Manero
Journal:  Expert Opin Investig Drugs       Date:  2011-05-10       Impact factor: 6.206

Review 9.  New insights into the treatment of multiple myeloma with histone deacetylase inhibitors.

Authors:  Michele Cea; Antonia Cagnetta; Marco Gobbi; Franco Patrone; Paul G Richardson; Teru Hideshima; Kenneth C Anderson
Journal:  Curr Pharm Des       Date:  2013       Impact factor: 3.116

10.  Autophagy is dispensable for Kmt2a/Mll-Mllt3/Af9 AML maintenance and anti-leukemic effect of chloroquine.

Authors:  Xiaoyi Chen; Jason Clark; Mark Wunderlich; Cuiqing Fan; Ashley Davis; Song Chen; Jun-Lin Guan; James C Mulloy; Ashish Kumar; Yi Zheng
Journal:  Autophagy       Date:  2017-02-15       Impact factor: 16.016

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.